SACRAMENTO, CA – Setting a national precedent, California will sell its own state-branded insulin, making life-saving diabetes medication affordable for millions. Governor Gavin Newsom announced that ...

The interchangeable biosimilar insulin glargine is approved for U.S. distribution through a newly established subsidiary, Lanexa Biologics. Tang added, “We are incredibly proud of what this ...

The FDA has approved Langlara, an interchangeable biosimilar to Lantus. The interchangeability designation allows pharmacists to substitute Langlara for Lantus without prescriber intervention in ...

Credit: Lannett. The approval was based on a comprehensive clinical program that included a phase 1 study comparing insulin glargine-aldy with insulin glargine in healthy male adults. Langlara is ...

PHILADELPHIA, May 04, 2026--(BUSINESS WIRE)--Lannett Company, Inc., Lanexa Biologics, a wholly owned subsidiary of Lannett, and Sunshine Lake Pharma today announced that the U.S. Food and Drug ...

Confession: I have a desk drawer filled with gel pens in a variety of colors (think neon pink, shimmery gold, deep black and beyond). I use them to write birthday cards for my friends and for my ...

(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ...

This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today. The nonprofit Civica will develop a ...

EXPECTING SOME FREEZING TEMPERATURES TO START ROLLING IN SCOTT. I FEEL LIKE THIS HAS TO BE THE BUZZ AT EVERY BREAK ROOM AT WORK THIS WEEK. HAVE YOU HEARD ABOUT THE COLD WEATHER THAT’S COMING? LOOK AT ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 1 diabetes had a higher time in range if they usually administered bolus insulin after a missed ...

Pharmacy chain CVS will pay $37.8 million for dispensing and billing health care plans including the military’s Tricare for more insulin than was prescribed for the pharmacy’s diabetic customers, ...

CVS reached a settlement on Tuesday with the U.S. Attorney for the Southern District of New York for over $37.75 million after the retailer was accused of over-dispensing insulin pens to patients.